These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 17972424)

  • 1. [Beta-blockers and arterial hypertension. Evidence-based medicine or excessive perseverance?].
    Verdecchia P; Angeli F; Achilli P; Castellani C; Repaci S; Ambrosio G
    G Ital Cardiol (Rome); 2007 Sep; 8(9):552-8. PubMed ID: 17972424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The development of new-onset type 2 diabetes associated with choosing a calcium channel blocker compared to a diuretic or beta-blocker.
    Kuti EL; Baker WL; White CM
    Curr Med Res Opin; 2007 Jun; 23(6):1239-44. PubMed ID: 17559720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atenolol as a comparator in outcome trials in hypertension: a correct choice in the past, but not for the future?
    Dahlöf B; Devereux RB; Kjeldsen SE; Lyle PA; Zhang Z; Edelman JM
    Blood Press; 2007; 16(1):6-12. PubMed ID: 17453746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Atenolol or metoprolol as beta-blocker in the treatment of hypertension].
    van den Born BJ; Brewster LM; Koopmans RP; van Montfrans GA
    Ned Tijdschr Geneeskd; 2005 Aug; 149(32):1808-9. PubMed ID: 16121668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are we misunderstanding beta-blockers.
    Cruickshank JM
    Int J Cardiol; 2007 Aug; 120(1):10-27. PubMed ID: 17433471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Do beta-blockers prevent coronary events in hypertensive patients?].
    Diévart F; Ragot S; Julien J; Herpin D
    Arch Mal Coeur Vaiss; 2005 Sep; 98(9):881-8. PubMed ID: 16231574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discordant effects of beta-blockade on central aortic systolic and brachial systolic blood pressure: considerations beyond the cuff.
    Epstein BJ; Anderson S
    Pharmacotherapy; 2007 Sep; 27(9):1322-33. PubMed ID: 17723086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular protection using beta-blockers: a critical review of the evidence.
    Bangalore S; Messerli FH; Kostis JB; Pepine CJ
    J Am Coll Cardiol; 2007 Aug; 50(7):563-72. PubMed ID: 17692739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blood pressure reduction and renin-angiotensin system inhibition for prevention of congestive heart failure: a meta-analysis.
    Verdecchia P; Angeli F; Cavallini C; Gattobigio R; Gentile G; Staessen JA; Reboldi G
    Eur Heart J; 2009 Mar; 30(6):679-88. PubMed ID: 19168534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The evolving role of β-adrenergic receptor blockers in managing hypertension.
    Poirier L; Lacourcière Y
    Can J Cardiol; 2012 May; 28(3):334-40. PubMed ID: 22595449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Managing hypertension using combination therapy.
    Frank J
    Am Fam Physician; 2008 May; 77(9):1279-86. PubMed ID: 18540493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiotensin II receptor blockers and myocardial infarction: an updated analysis of randomized clinical trials.
    Volpe M; Tocci G; Sciarretta S; Verdecchia P; Trimarco B; Mancia G
    J Hypertens; 2009 May; 27(5):941-6. PubMed ID: 19381108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Verapamil-sustained release-based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: an INternational VErapamil SR-Trandolapril (INVEST) substudy.
    Bangalore S; Messerli FH; Cohen JD; Bacher PH; Sleight P; Mancia G; Kowey P; Zhou Q; Champion A; Pepine CJ;
    Am Heart J; 2008 Aug; 156(2):241-7. PubMed ID: 18657652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A 16-week, randomized, double-blind, placebo-controlled, crossover trial to quantify the combined effect of an angiotensin-converting enzyme inhibitor and a beta-blocker on blood pressure reduction.
    Wald DS; Law M; Mills S; Bestwick JP; Morris JK; Wald NJ
    Clin Ther; 2008 Nov; 30(11):2030-9. PubMed ID: 19108791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardioprotection with beta-blockers: myths, facts and Pascal's wager.
    Messerli FH; Bangalore S; Yao SS; Steinberg JS
    J Intern Med; 2009 Sep; 266(3):232-41. PubMed ID: 19702791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus.
    Bangalore S; Parkar S; Grossman E; Messerli FH
    Am J Cardiol; 2007 Oct; 100(8):1254-62. PubMed ID: 17920367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nebivolol: a third-generation beta-blocker for hypertension.
    Cheng JW
    Clin Ther; 2009 Mar; 31(3):447-62. PubMed ID: 19393838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of essential hypertension with calcium channel blockers: what is the place of lercanidipine?
    Burnier M; Pruijm M; Wuerzner G
    Expert Opin Drug Metab Toxicol; 2009 Aug; 5(8):981-7. PubMed ID: 19619074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Do beta-blockers have a role in the modern treatment of arterial hypertension?].
    Horký K
    Vnitr Lek; 1996 Jun; 42(6):420-5. PubMed ID: 8928415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are tolerability concerns a class effect of beta-blockers in treating patients with hypertension?
    Kountz DS
    Postgrad Med; 2009 Jan; 121(1):14-24. PubMed ID: 19179810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.